Nov. 24, 2009
Pfizer (China) Research and Development Co. Ltd. will partner with the Wuhan National Bioindustry Base Construction and Management Office to establish a Pfizer research and development center in Wuhan City, Hubei Province.
The company also plans to expand its existing Shanghai R&D center, which will continue to be the main operations center for R&D activities in China. The new Wuhan center will focus on global clinical drug development, including Phase I to IV clinical trials and aims to hire 200 employees within three years.
Pfizer currently has 69 products registered in China - 41 of which are nationally reimbursed drugs and 9 of which are on the grassroots National Essential Drug List.